134 related articles for article (PubMed ID: 36376377)
21. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis.
Iankova I; Petersen RK; Annicotte JS; Chavey C; Hansen JB; Kratchmarova I; Sarruf D; Benkirane M; Kristiansen K; Fajas L
Mol Endocrinol; 2006 Jul; 20(7):1494-505. PubMed ID: 16484339
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).
Chiu YL; Cao H; Jacque JM; Stevenson M; Rana TM
J Virol; 2004 Mar; 78(5):2517-29. PubMed ID: 14963154
[TBL] [Abstract][Full Text] [Related]
23. Reversible phosphorylation of cyclin T1 promotes assembly and stability of P-TEFb.
Huang F; Nguyen TT; Echeverria I; Rakesh R; Cary DC; Paculova H; Sali A; Weiss A; Peterlin BM; Fujinaga K
Elife; 2021 Nov; 10():. PubMed ID: 34821217
[TBL] [Abstract][Full Text] [Related]
24. G-actin participates in RNA polymerase II-dependent transcription elongation by recruiting positive transcription elongation factor b (P-TEFb).
Qi T; Tang W; Wang L; Zhai L; Guo L; Zeng X
J Biol Chem; 2011 Apr; 286(17):15171-81. PubMed ID: 21378166
[TBL] [Abstract][Full Text] [Related]
25. Targeting cyclin-dependent kinase 9 in cancer therapy.
Shen YL; Wang YM; Zhang YX; Ma SJ; Yang LH; Zhao CG; Huang XY
Acta Pharmacol Sin; 2022 Jul; 43(7):1633-1645. PubMed ID: 34811514
[TBL] [Abstract][Full Text] [Related]
26. Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II.
Lu H; Yu D; Hansen AS; Ganguly S; Liu R; Heckert A; Darzacq X; Zhou Q
Nature; 2018 Jun; 558(7709):318-323. PubMed ID: 29849146
[TBL] [Abstract][Full Text] [Related]
27. A single point mutation in cyclin T1 eliminates binding to Hexim1, Cdk9 and RNA but not to AFF4 and enforces repression of HIV transcription.
Kuzmina A; Verstraete N; Galker S; Maatook M; Bensaude O; Taube R
Retrovirology; 2014 Jul; 11():51. PubMed ID: 24985467
[TBL] [Abstract][Full Text] [Related]
28. Catalytic activity of Cdk9 is required for nuclear co-localization of the Cdk9/cyclin T1 (P-TEFb) complex.
Napolitano G; Majello B; Lania L
J Cell Physiol; 2003 Oct; 197(1):1-7. PubMed ID: 12942536
[TBL] [Abstract][Full Text] [Related]
29. The Cdk9 and cyclin T subunits of TAK/P-TEFb localize to splicing factor-rich nuclear speckle regions.
Herrmann CH; Mancini MA
J Cell Sci; 2001 Apr; 114(Pt 8):1491-503. PubMed ID: 11282025
[TBL] [Abstract][Full Text] [Related]
30. Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription.
Liu P; Xiang Y; Fujinaga K; Bartholomeeusen K; Nilson KA; Price DH; Peterlin BM
J Biol Chem; 2014 Apr; 289(14):9918-25. PubMed ID: 24515107
[TBL] [Abstract][Full Text] [Related]
31. P-TEFb Kinase Activity Is Essential for Global Transcription, Resumption of Meiosis and Embryonic Genome Activation in Pig.
Oqani RK; Lin T; Lee JE; Choi KM; Shin HY; Jin DI
PLoS One; 2016; 11(3):e0152254. PubMed ID: 27011207
[TBL] [Abstract][Full Text] [Related]
32. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates.
Sansó M; Levin RS; Lipp JJ; Wang VY; Greifenberg AK; Quezada EM; Ali A; Ghosh A; Larochelle S; Rana TM; Geyer M; Tong L; Shokat KM; Fisher RP
Genes Dev; 2016 Jan; 30(1):117-31. PubMed ID: 26728557
[TBL] [Abstract][Full Text] [Related]
33. Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
Zhou M; Huang K; Jung KJ; Cho WK; Klase Z; Kashanchi F; Pise-Masison CA; Brady JN
J Virol; 2009 Jan; 83(2):1036-44. PubMed ID: 18971272
[TBL] [Abstract][Full Text] [Related]
34. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract][Full Text] [Related]
35. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
36. Functional inactivation of Cdk9 through oligomerization chain reaction.
Napolitano G; Mazzocco A; Fraldi A; Majello B; Lania L
Oncogene; 2003 Jul; 22(31):4882-8. PubMed ID: 12894230
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Qing Y; Wang X; Wang H; Hu P; Li H; Yu X; Zhu M; Wang Z; Zhu Y; Xu J; Guo Q; Hui H
Cell Commun Signal; 2021 Aug; 19(1):83. PubMed ID: 34372855
[TBL] [Abstract][Full Text] [Related]
38. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor.
Michels AA; Fraldi A; Li Q; Adamson TE; Bonnet F; Nguyen VT; Sedore SC; Price JP; Price DH; Lania L; Bensaude O
EMBO J; 2004 Jul; 23(13):2608-19. PubMed ID: 15201869
[TBL] [Abstract][Full Text] [Related]
39. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
Paparidis NF; Durvale MC; Canduri F
Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
[TBL] [Abstract][Full Text] [Related]
40. Brd4-dependent CDK9 expression induction upon sustained pharmacological inhibition of P-TEFb kinase activity.
Liu R
Biochem Biophys Res Commun; 2023 Sep; 671():75-79. PubMed ID: 37295357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
